Rapid onset type-1 diabetes and diabetic ketoacidosis secondary to nivolumab immunotherapy: a review of existing literature

Nivolumab is a programmed cell death receptor (PD-1) inhibitor that is increasingly used for various malignancies, both as a first line agent and as salvage therapy. Being a PD-1/PD-1 ligand checkpoint inhibitor, it is known to cause autoimmune inflammation of various organs and has been associated...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Case Rep
Main Authors: Abdullah, Hafez Mohammad Ammar, Elnair, Radowan, Khan, Uzma Ikhtiar, Omar, Muhammad, Morey-Vargas, Oscar L
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2019
Assuntos:
Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6721076/
https://ncbi.nlm.nih.gov/pubmed/31451458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2019-229568
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados